# Shidong Jia

> Shidong Jia, MD, PhD, is the founder and global CEO of Predicine, a Silicon Valley precision-oncology company building multi-omic liquid biopsy tests that read cancer from blood and urine. Trained as a physician-scientist at Harbin Medical University, Peking Union Medical College, Dana-Farber and Harvard, he ran oncology biomarker strategy at Genentech before leaving to start Predicine in 2015. His pitch is simple: precision diagnostics to enable precision medicine, built 'From Pharma, For Pharma.'

- **Role:** Founder & Global CEO at Predicine
- **Organizations:** Predicine, Genentech (former), Novartis Institutes for BioMedical Research (former), Dana-Farber Cancer Institute (former), Harvard Medical School (former)
- **Nationality:** American (born in China)
- **Education:** MD, Harbin Medical University, PhD, Peking Union Medical College, Postdoctoral training (oncology), Dana-Farber Cancer Institute / Harvard Medical School
- **Known for:** Founded and scaled Predicine, a global precision-oncology diagnostics company (~89 employees, $27M+ raised), Identified p110beta as a drug target for PTEN-deficient tumors, seeding clinical development of p110beta inhibitors, Led Predicine to FDA Breakthrough Device Designation for a liquid biopsy NGS assay

## Career timeline

- **2010** — Joined Genentech as scientist and biomarker team lead, running oncology biomarker strategy and drug/diagnostics co-development
- **2014** — Became Editor-in-Chief of the Journal of Circulating Biomarkers (through 2018)
- **2015** — Founded Predicine to advance precision diagnostics and precision medicine
- **2020** — Predicine raised a Series B round; partnered with Epic Sciences to expand liquid biopsy offerings to biopharma
- **2022** — Predicine's liquid biopsy NGS assay granted FDA Breakthrough Device Designation
- **2026** — Speaking at the 10th Liquid Biopsy for Precision Oncology Summit on end-to-end liquid biopsy for drug development

## Achievements

- Founded and scaled Predicine, a global precision-oncology diagnostics company (~89 employees, $27M+ raised)
- Identified p110beta as a drug target for PTEN-deficient tumors, seeding clinical development of p110beta inhibitors
- Led Predicine to FDA Breakthrough Device Designation for a liquid biopsy NGS assay
- Awarded the P.A.R.T. Investigatorship Award from Dana-Farber Cancer Institute
- Served as Editor-in-Chief of the Journal of Circulating Biomarkers (2014-2018)
- Built proprietary combined cell-free DNA and RNA liquid biopsy technology

## Latest updates

- **2026-02** — Presenting at the 10th Liquid Biopsy for Precision Oncology Summit on end-to-end liquid biopsy solutions supporting KRAS, ADC, radioligand and broader oncology drug development
- **2022-09** — Predicine's liquid biopsy NGS assay received FDA Breakthrough Device Designation

## Links

- Website: https://predicine.com
- LinkedIn: https://www.linkedin.com/in/shidong-jia-52813017
- Twitter/X: https://x.com/shidong_jia
- Facebook: https://facebook.com/predicine/

---

Profile page: https://yespress.io/shidong-jia
Published by YesPress — https://yespress.io
Last updated: 2026-07-29